Anshul Maheshwari Sells 11,636 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anshul Maheshwari sold 11,636 shares of SiBone stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $20.11, for a total value of $233,999.96. Following the sale, the insider owned 223,284 shares of the company’s stock, valued at approximately $4,490,241.24. This represents a 4.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Anshul Maheshwari also recently made the following trade(s):

• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total transaction of $87,002.25.
• On Thursday, July 2nd, Anshul Maheshwari sold 3,317 shares of SiBone stock. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09.

SiBone Stock Performance

Shares of NASDAQ SIBN opened at $19.20 on Friday. The company has a 50-day simple moving average of $17.81 and a 200-day simple moving average of $15.42. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The company has a market cap of $851.52 million, a PE ratio of -56.47 and a beta of 0.66. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. On average, equities analysts anticipate that SiBone will post -0.4 earnings per share for the current year.

Hedge Funds Weigh In On SiBone

A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its stake in shares of SiBone by 98.5% during the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after buying an additional 736 shares during the period. Versant Capital Management Inc raised its position in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the last quarter. Larson Financial Group LLC boosted its holdings in SiBone by 42.3% in the fourth quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after acquiring an additional 1,061 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in SiBone by 4.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock valued at $733,000 after acquiring an additional 1,459 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on SIBN. TD Cowen lifted their price objective on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Truist Financial reiterated a “buy” rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. UBS Group raised their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, SiBone currently has an average rating of “Moderate Buy” and a consensus target price of $24.17.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.